New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
07:23 EDTPCRXPacira Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Pacira Pharmaceuticals to Overweight citing the FDA approval of new manufacturing capacity for Exparel. Piper believes Pacira is now able to meet the continued growth in Exparel demand and raised its price target for shares to $84 from $75.
News For PCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
06:31 EDTPCRXPacira announces positive data in study of Exparel
Subscribe for More Information
March 23, 2015
16:32 EDTPCRXPacira announces results of two data presentations for Exparel
Pacira Pharmaceuticals announced results of two data presentations on the impact of Exparel on postsurgical opioid requirements in patients undergoing hysterectomy or mastectomy. The data were presented during two poster sessions at the annual meeting of the International Anesthesia Research Society, or IARS, being held in Honolulu March 21-24. The first study compared the efficacy of Exparel to bupivacaine HCl when infiltrated into the transversus abdominis plane, or TAP, to provide postsurgical analgesia following robotic assisted hysterectomy in 60 women. Blinded assessments of pain intensity, opioid intake and incidence of adverse events were taken for up to 72 hours after the procedure. In comparison to the bupivacaine HCl treatment group, patients who received TAP infiltration with Exparel had: Significantly decreased total opioid intake in first 72 hours; Significantly decreased incidence of nausea and vomiting in the first 72 hours; Significantly lower maximal pain intensity at all time points.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use